Brief: Immix Biopharma Unit Announces Start Of Nxc-201 Engineering Batches At U.S. Car-T Manufacturing Site
26/05/2023 14:54
May 26 (Reuters) - Immix Biopharma Inc IMMX.O :
* IMMIX BIOPHARMA SUBSIDIARY NEXCELLA ANNOUNCES COMMENCEMENT
OF
NXC-201 ENGINEERING BATCHES AT ITS U.S. CAR-T MANUFACTURING SITE
* IMMIX BIOPHARMA INC - NEXCELLA PLANS TO SUBMIT DATA TO FDA
IN AL
AMYLOIDOSIS ONCE 30-40 PATIENTS ARE TREATED WITH NXC-201
Source text for Eikon: ID:nGNX2mJktJ
Further company coverage: IMMX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary